- Home
- Publications
- Publication Search
- Publication Details
Title
Might dolutegravir be part of a functional cure for HIV?
Authors
Keywords
-
Journal
CANADIAN JOURNAL OF MICROBIOLOGY
Volume 62, Issue 5, Pages 375-382
Publisher
Canadian Science Publishing
Online
2016-04-01
DOI
10.1139/cjm-2015-0725
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure
- (2016) Alyssa R. Martin et al. Annual Review of Medicine
- Select host restriction factors are associated with HIV persistence during antiretroviral therapy
- (2015) Mohamed Abdel-Mohsen et al. AIDS
- Dolutegravir inhibits HIV-1 Env evolution in primary human cells
- (2015) Thibault Mesplède et al. AIDS
- Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir ResistanceIn Vitro
- (2015) Takahiro Seki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- HIV therapeutic vaccines: moving towards a functional cure
- (2015) Geetha H Mylvaganam et al. CURRENT OPINION IN IMMUNOLOGY
- Advancing the HIV cure agenda
- (2015) John Thornhill et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout
- (2015) Nathan Osman et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Genome editing strategies: potential tools for eradicating HIV-1/AIDS
- (2015) Kamel Khalili et al. JOURNAL OF NEUROVIROLOGY
- Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity
- (2015) Kaitlin Anstett et al. JOURNAL OF VIROLOGY
- The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance
- (2015) Jiaming Liang et al. JOURNAL OF VIROLOGY
- Post-treatment control of HIV infection
- (2015) Jessica M. Conway et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impaired Th17 polarization of phenotypically naive CD4+ T-cells during chronic HIV-1 infection and potential restoration with early ART
- (2015) Sandrina DaFonseca et al. Retrovirology
- Towards an HIV-1 cure: measuring the latent reservoir
- (2015) Katherine M. Bruner et al. TRENDS IN MICROBIOLOGY
- Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
- (2015) Thibault Mesplède et al. Viruses-Basel
- The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency
- (2015) Guillaume Mousseau et al. mBio
- Review
- (2015) Francesco R. Simonetti et al. Current Opinion in HIV and AIDS
- Towards an HIV cure based on targeted killing of infected cells
- (2015) Barna Dey et al. Current Opinion in HIV and AIDS
- Current state and limitations of daily oral therapy for treatment
- (2015) Daniel A. Solomon et al. Current Opinion in HIV and AIDS
- How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?
- (2015) Jintanat Ananworanich et al. Current Opinion in HIV and AIDS
- Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
- (2015) Mario Cruciani et al. Patient Preference and Adherence
- CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy
- (2015) Kristina Allers et al. Current Opinion in Virology
- Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation
- (2015) Guochun Jiang et al. PLoS Pathogens
- Will drug resistance against dolutegravir in initial therapy ever occur?
- (2015) Mark A. Wainberg et al. Frontiers in Pharmacology
- Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase
- (2015) Peter K. Quashie et al. JOURNAL OF VIROLOGY
- A cure for HIV: is it in sight?
- (2014) Matthew Pace et al. Expert Review of Anti-Infective Therapy
- Recent developments in the search for a cure for HIV-1 infection: Targeting the latent reservoir for HIV-1
- (2014) Janet D. Siliciano et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Sooner, the Better: More Evidence That Early Antiretroviral Therapy Lowers Viral Reservoirs in HIV-Infected Infants
- (2014) Jonathan Z. Li et al. JOURNAL OF INFECTIOUS DISEASES
- HIV Type 1 (HIV-1) Proviral Reservoirs Decay Continuously Under Sustained Virologic Control in HIV-1–Infected Children Who Received Early Treatment
- (2014) Katherine Luzuriaga et al. JOURNAL OF INFECTIOUS DISEASES
- Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells
- (2014) M. J. Buzon et al. JOURNAL OF VIROLOGY
- Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys
- (2014) James B. Whitney et al. NATURE
- The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
- (2014) Melissa Wares et al. Retrovirology
- Immunologic strategies for HIV-1 remission and eradication
- (2014) D. H. Barouch et al. SCIENCE
- Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
- (2014) Kirsten White et al. Viruses-Basel
- Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
- (2014) Thibault Mesplède et al. Viruses-Basel
- Current Perspectives on HIV-1 Antiretroviral Drug Resistance
- (2014) Pinar Iyidogan et al. Viruses-Basel
- The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
- (2014) Mark Wainberg et al. Journal of the International AIDS Society
- Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase
- (2013) Peter K. Quashie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts
- (2013) Laurent Hocqueloux et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size
- (2013) Vivek Jain et al. JOURNAL OF INFECTIOUS DISEASES
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs
- (2013) Christine Katlama et al. LANCET
- Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
- (2013) Dan H. Barouch et al. NATURE
- Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
- (2013) Thibault Mesplède et al. Retrovirology
- Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium
- (2013) Damian FJ Purcell et al. Retrovirology
- Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
- (2013) Asier Sáez-Cirión et al. PLoS Pathogens
- Evolution of HIV integrase resistance mutations
- (2012) Peter K. Quashie et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Emerging patterns and implications of HIV-1 integrase inhibitor resistance
- (2012) Anna Maria Geretti et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection
- (2012) Jintanat Ananworanich et al. PLoS One
- Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection
- (2012) N. M. Archin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
- (2011) Kendra E. Hightower et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
- (2011) P. K. Quashie et al. JOURNAL OF VIROLOGY
- Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
- (2011) S. Hare et al. MOLECULAR PHARMACOLOGY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evidence for the cure of HIV infection by CCR5 32/ 32 stem cell transplantation
- (2010) K. Allers et al. BLOOD
- Long-Term Control of HIV byCCR5Delta32/Delta32 Stem-Cell Transplantation
- (2009) Gero Hütter et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More